Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.

Item

http://www.wikidata.org/entity/Q55008089

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Switching Reference Medicines ...... e Review of Clinical Outcomes.

@en

Switching Reference Medicines ...... e Review of Clinical Outcomes.

@nl

type

Item

label

Switching Reference Medicines ...... e Review of Clinical Outcomes.

@en

Switching Reference Medicines ...... e Review of Clinical Outcomes.

@nl

prefLabel

Switching Reference Medicines ...... e Review of Clinical Outcomes.

@en

Switching Reference Medicines ...... e Review of Clinical Outcomes.

@nl

P1476

Switching Reference Medicines ...... e Review of Clinical Outcomes.

@en

P2093

Andrew Blauvelt

http://www.w3.org/2001/XMLSchema#string

Gillian Woollett

http://www.w3.org/2001/XMLSchema#string

Hillel P Cohen

http://www.w3.org/2001/XMLSchema#string

Robert M Rifkin

http://www.w3.org/2001/XMLSchema#string

Sameer B Gokhale

http://www.w3.org/2001/XMLSchema#string

Silvio Danese

http://www.w3.org/2001/XMLSchema#string

P2860

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.

Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician.

Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.

It's in your hands: the value of handsearching in conducting systematic reviews of public health interventions.

A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.

The safety of switching between therapeutic proteins.

Immunogenicity of therapeutic proteins: influence of aggregation.

Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series.

P2888

s40265-018-0881-y

P304

463-478

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-018-0881-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1101323445

http://www.w3.org/2001/XMLSchema#string

P698

29500555

http://www.w3.org/2001/XMLSchema#string

P932

5854749

http://www.w3.org/2001/XMLSchema#string